Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02614612 · ClinicalTrials.gov registry record · Phase 1
Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD
A Phase 1 study, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 31
- Enrollment target
NCT02614612: Completed Phase 1 study, sponsored by Incyte Corporation.
NCT02614612 is a Phase 1 study that has completed, run by Incyte Corporation. The registered enrollment target is 31 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02614612, a Phase 1 study, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 31 participants
- Enrollment target
Study Summary
To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).
Interventions
- DRUG Itacitinib (200 mg)
- DRUG Itacitinib (300 mg)
- DRUG prednisone or methylprednisolone (corticosteroids)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-08 |
| Phase | Phase 1 |
What the finished NCT02614612 record still lists
NCT02614612 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (48% lower).
The record links to 0 conditions, and to 3 interventions - of which Itacitinib (200 mg) is the first listed.
NCT02614612 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02614612 about?
NCT02614612 is a clinical study titled "Study of Itacitinib in Combination With Corticosteroids for the Treatment of Acute GVHD". To determine if Itacitinib in combination with corticosteroids is safe and tolerable in patients with Grade IIB-IVD acute graft-versus-host disease (GVHD).
What is the current status of trial NCT02614612?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 31 participants. The study started on 2015-12. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02614612?
The interventions under investigation include: Itacitinib (200 mg) (DRUG), Itacitinib (300 mg) (DRUG), prednisone or methylprednisolone (corticosteroids) (DRUG).
Who is sponsoring clinical trial NCT02614612?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02614612's enrollment target sits among peer trials
31 1322nd of 2000 higher than 669 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia